Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Tamal Chakraborti, PhD

Advertisement

Articles by Tamal Chakraborti, PhD

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

ByGeorge Shashaty, MD,Raymond Frankewich, PhD,Tamal Chakraborti, PhD,Jasti Choudary, PhD,Suliman Al-fayoumi, PhD,Alice Kacuba, RN, MSN,Sonia Castillo, PhD,Kathy Robie-suh, MD, PhD,Dwaine Rieves, MD,Karen Weiss, MD,Richard Pazdur, MD
December 1st 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.

Advertisement

Latest Updated Articles

  • Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis
    Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

    December 1st 2006



Advertisement
Advertisement

Trending on CancerNetwork

1

KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS

2

Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028

3

How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?

4

Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer

5

AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us